nodes	percent_of_prediction	percent_of_DWPC	metapath
Lithium—IMPA2—pancreas—bile duct cancer	0.0347	0.151	CbGeAlD
Lithium—GSK3A—pancreas—bile duct cancer	0.0296	0.129	CbGeAlD
Lithium—IMPA1—liver—bile duct cancer	0.0294	0.128	CbGeAlD
Lithium—GRIA3—liver—bile duct cancer	0.025	0.109	CbGeAlD
Lithium—IMPA2—liver—bile duct cancer	0.0221	0.0963	CbGeAlD
Lithium—GSK3B—liver—bile duct cancer	0.0216	0.0945	CbGeAlD
Lithium—GSK3A—liver—bile duct cancer	0.0188	0.0821	CbGeAlD
Lithium—IMPA2—lymph node—bile duct cancer	0.0169	0.0738	CbGeAlD
Lithium—GSK3B—lymph node—bile duct cancer	0.0166	0.0724	CbGeAlD
Lithium—GSK3A—lymph node—bile duct cancer	0.0144	0.063	CbGeAlD
Lithium—GSK3A—Integrated Pancreatic Cancer Pathway—EGFR—bile duct cancer	0.0014	0.00181	CbGpPWpGaD
Lithium—GSK3A—Signaling by EGFR—KRAS—bile duct cancer	0.00139	0.0018	CbGpPWpGaD
Lithium—GSK3B—Downstream signaling of activated FGFR—NRAS—bile duct cancer	0.00138	0.00179	CbGpPWpGaD
Lithium—GSK3A—Signaling by EGFR in Cancer—KRAS—bile duct cancer	0.00138	0.00179	CbGpPWpGaD
Lithium—GSK3A—B Cell Activation—EGFR—bile duct cancer	0.00137	0.00178	CbGpPWpGaD
Lithium—GSK3A—Signaling by PDGF—KRAS—bile duct cancer	0.00137	0.00178	CbGpPWpGaD
Lithium—GSK3A—Signaling by SCF-KIT—IL6—bile duct cancer	0.00137	0.00178	CbGpPWpGaD
Lithium—GSK3A—Downstream signaling of activated FGFR—HRAS—bile duct cancer	0.00137	0.00177	CbGpPWpGaD
Lithium—GSK3B—Disease—RNF43—bile duct cancer	0.00137	0.00177	CbGpPWpGaD
Lithium—GSK3B—Signaling by ERBB4—NRAS—bile duct cancer	0.00136	0.00176	CbGpPWpGaD
Lithium—GSK3B—DNA Damage Response (only ATM dependent)—TP53—bile duct cancer	0.00136	0.00176	CbGpPWpGaD
Lithium—GSK3A—Signaling by ERBB4—HRAS—bile duct cancer	0.00135	0.00175	CbGpPWpGaD
Lithium—GSK3B—Senescence and Autophagy in Cancer—HRAS—bile duct cancer	0.00134	0.00173	CbGpPWpGaD
Lithium—GSK3B—Axon guidance—MET—bile duct cancer	0.00133	0.00173	CbGpPWpGaD
Lithium—GSK3A—Integrated Pancreatic Cancer Pathway—KRAS—bile duct cancer	0.00132	0.00171	CbGpPWpGaD
Lithium—GSK3B—Signaling by SCF-KIT—EGFR—bile duct cancer	0.00132	0.00171	CbGpPWpGaD
Lithium—GSK3A—NGF signalling via TRKA from the plasma membrane—EGFR—bile duct cancer	0.00131	0.00171	CbGpPWpGaD
Lithium—GSK3A—Downstream signaling of activated FGFR—IL6—bile duct cancer	0.00131	0.0017	CbGpPWpGaD
Lithium—GSK3B—Downstream signal transduction—NRAS—bile duct cancer	0.0013	0.00168	CbGpPWpGaD
Lithium—GSK3B—DNA Damage Response (only ATM dependent)—HRAS—bile duct cancer	0.0013	0.00168	CbGpPWpGaD
Lithium—GSK3A—B Cell Activation—KRAS—bile duct cancer	0.0013	0.00168	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—RNF43—bile duct cancer	0.00129	0.00168	CbGpPWpGaD
Lithium—GSK3B—Signaling by FGFR—NRAS—bile duct cancer	0.00129	0.00168	CbGpPWpGaD
Lithium—GSK3A—Insulin Signaling—HRAS—bile duct cancer	0.00129	0.00168	CbGpPWpGaD
Lithium—GSK3A—Signaling by ERBB4—IL6—bile duct cancer	0.00129	0.00167	CbGpPWpGaD
Lithium—GSK3B—Signaling by ERBB2—NRAS—bile duct cancer	0.00129	0.00167	CbGpPWpGaD
Lithium—GSK3A—Downstream signal transduction—HRAS—bile duct cancer	0.00129	0.00167	CbGpPWpGaD
Lithium—GSK3B—Senescence and Autophagy in Cancer—IL6—bile duct cancer	0.00128	0.00166	CbGpPWpGaD
Lithium—GSK3B—DAP12 signaling—NRAS—bile duct cancer	0.00128	0.00166	CbGpPWpGaD
Lithium—GSK3A—Signaling by FGFR—HRAS—bile duct cancer	0.00128	0.00166	CbGpPWpGaD
Lithium—GSK3A—Signaling by ERBB2—HRAS—bile duct cancer	0.00127	0.00165	CbGpPWpGaD
Lithium—GSK3A—DAP12 signaling—HRAS—bile duct cancer	0.00127	0.00164	CbGpPWpGaD
Lithium—GSK3B—Downstream signaling events of B Cell Receptor (BCR)—NRAS—bile duct cancer	0.00126	0.00164	CbGpPWpGaD
Lithium—GSK3B—Downstream signaling of activated FGFR—EGFR—bile duct cancer	0.00126	0.00163	CbGpPWpGaD
Lithium—GSK3A—Downstream signaling events of B Cell Receptor (BCR)—HRAS—bile duct cancer	0.00125	0.00162	CbGpPWpGaD
Lithium—GSK3B—Developmental Biology—SMAD4—bile duct cancer	0.00124	0.00161	CbGpPWpGaD
Lithium—GSK3B—Signaling by SCF-KIT—KRAS—bile duct cancer	0.00124	0.00161	CbGpPWpGaD
Lithium—GSK3A—NGF signalling via TRKA from the plasma membrane—KRAS—bile duct cancer	0.00124	0.00161	CbGpPWpGaD
Lithium—GSK3B—Signaling by ERBB4—EGFR—bile duct cancer	0.00124	0.00161	CbGpPWpGaD
Lithium—GSK3A—Downstream signal transduction—IL6—bile duct cancer	0.00123	0.0016	CbGpPWpGaD
Lithium—GSK3A—Signaling by FGFR—IL6—bile duct cancer	0.00122	0.00159	CbGpPWpGaD
Lithium—GSK3A—Signaling by ERBB2—IL6—bile duct cancer	0.00122	0.00158	CbGpPWpGaD
Lithium—GSK3A—DAP12 signaling—IL6—bile duct cancer	0.00121	0.00157	CbGpPWpGaD
Lithium—GSK3B—Fc epsilon receptor (FCERI) signaling—NRAS—bile duct cancer	0.0012	0.00156	CbGpPWpGaD
Lithium—GSK3B—DAP12 interactions—NRAS—bile duct cancer	0.0012	0.00156	CbGpPWpGaD
Lithium—GSK3B—Signaling by FGFR in disease—NRAS—bile duct cancer	0.0012	0.00156	CbGpPWpGaD
Lithium—GSK3B—Signaling by EGFR—NRAS—bile duct cancer	0.00119	0.00155	CbGpPWpGaD
Lithium—GSK3A—Fc epsilon receptor (FCERI) signaling—HRAS—bile duct cancer	0.00119	0.00155	CbGpPWpGaD
Lithium—GSK3A—DAP12 interactions—HRAS—bile duct cancer	0.00119	0.00155	CbGpPWpGaD
Lithium—GSK3A—Signaling by FGFR in disease—HRAS—bile duct cancer	0.00119	0.00155	CbGpPWpGaD
Lithium—GSK3B—Downstream signaling of activated FGFR—KRAS—bile duct cancer	0.00119	0.00154	CbGpPWpGaD
Lithium—GSK3B—Downstream signal transduction—EGFR—bile duct cancer	0.00118	0.00153	CbGpPWpGaD
Lithium—GSK3B—Signaling by EGFR in Cancer—NRAS—bile duct cancer	0.00118	0.00153	CbGpPWpGaD
Lithium—GSK3A—Signaling by EGFR—HRAS—bile duct cancer	0.00118	0.00153	CbGpPWpGaD
Lithium—GSK3B—Signaling by FGFR—EGFR—bile duct cancer	0.00118	0.00153	CbGpPWpGaD
Lithium—GSK3B—Signaling by PDGF—NRAS—bile duct cancer	0.00118	0.00153	CbGpPWpGaD
Lithium—GSK3B—Disease—IDH1—bile duct cancer	0.00117	0.00152	CbGpPWpGaD
Lithium—GSK3A—Integrated Pancreatic Cancer Pathway—TP53—bile duct cancer	0.00117	0.00152	CbGpPWpGaD
Lithium—GSK3B—Signaling by ERBB2—EGFR—bile duct cancer	0.00117	0.00152	CbGpPWpGaD
Lithium—GSK3A—Signaling by EGFR in Cancer—HRAS—bile duct cancer	0.00117	0.00152	CbGpPWpGaD
Lithium—GSK3B—Signaling by ERBB4—KRAS—bile duct cancer	0.00117	0.00152	CbGpPWpGaD
Lithium—GSK3B—DAP12 signaling—EGFR—bile duct cancer	0.00117	0.00151	CbGpPWpGaD
Lithium—GSK3A—Signaling by PDGF—HRAS—bile duct cancer	0.00117	0.00151	CbGpPWpGaD
Lithium—GRIA3—Neuronal System—HRAS—bile duct cancer	0.00116	0.0015	CbGpPWpGaD
Lithium—GSK3B—Downstream signaling events of B Cell Receptor (BCR)—EGFR—bile duct cancer	0.00115	0.00149	CbGpPWpGaD
Lithium—GSK3A—Signaling by FGFR in disease—IL6—bile duct cancer	0.00114	0.00148	CbGpPWpGaD
Lithium—GSK3A—DAP12 interactions—IL6—bile duct cancer	0.00114	0.00148	CbGpPWpGaD
Lithium—GSK3A—Fc epsilon receptor (FCERI) signaling—IL6—bile duct cancer	0.00114	0.00148	CbGpPWpGaD
Lithium—GSK3A—Signaling by EGFR—IL6—bile duct cancer	0.00113	0.00147	CbGpPWpGaD
Lithium—GSK3A—Signaling by EGFR in Cancer—IL6—bile duct cancer	0.00112	0.00145	CbGpPWpGaD
Lithium—GSK3B—Downstream signal transduction—KRAS—bile duct cancer	0.00112	0.00145	CbGpPWpGaD
Lithium—GSK3A—Signaling by PDGF—IL6—bile duct cancer	0.00112	0.00145	CbGpPWpGaD
Lithium—GSK3B—B Cell Activation—NRAS—bile duct cancer	0.00111	0.00145	CbGpPWpGaD
Lithium—GSK3B—Axon guidance—MMP2—bile duct cancer	0.00111	0.00144	CbGpPWpGaD
Lithium—GSK3B—Signaling by FGFR—KRAS—bile duct cancer	0.00111	0.00144	CbGpPWpGaD
Lithium—GSK3A—Signaling by NGF—NRAS—bile duct cancer	0.00111	0.00144	CbGpPWpGaD
Lithium—GSK3B—Signaling by ERBB2—KRAS—bile duct cancer	0.00111	0.00144	CbGpPWpGaD
Lithium—GSK3A—B Cell Activation—HRAS—bile duct cancer	0.0011	0.00143	CbGpPWpGaD
Lithium—GSK3B—DAP12 signaling—KRAS—bile duct cancer	0.0011	0.00143	CbGpPWpGaD
Lithium—GSK3B—DAP12 interactions—EGFR—bile duct cancer	0.0011	0.00142	CbGpPWpGaD
Lithium—GSK3B—Fc epsilon receptor (FCERI) signaling—EGFR—bile duct cancer	0.0011	0.00142	CbGpPWpGaD
Lithium—GSK3B—Signaling by FGFR in disease—EGFR—bile duct cancer	0.0011	0.00142	CbGpPWpGaD
Lithium—IMPA2—Metabolism—PTGS2—bile duct cancer	0.00109	0.00142	CbGpPWpGaD
Lithium—GSK3B—Signaling by EGFR—EGFR—bile duct cancer	0.00109	0.00141	CbGpPWpGaD
Lithium—GSK3B—Downstream signaling events of B Cell Receptor (BCR)—KRAS—bile duct cancer	0.00109	0.00141	CbGpPWpGaD
Lithium—GSK3B—Signaling by NGF—ERBB2—bile duct cancer	0.00108	0.0014	CbGpPWpGaD
Lithium—GSK3B—Signaling by EGFR in Cancer—EGFR—bile duct cancer	0.00108	0.0014	CbGpPWpGaD
Lithium—GSK3B—Signaling by PDGF—EGFR—bile duct cancer	0.00107	0.00139	CbGpPWpGaD
Lithium—GSK3B—NGF signalling via TRKA from the plasma membrane—NRAS—bile duct cancer	0.00107	0.00138	CbGpPWpGaD
Lithium—GSK3B—Signaling by SCF-KIT—HRAS—bile duct cancer	0.00106	0.00137	CbGpPWpGaD
Lithium—GSK3A—NGF signalling via TRKA from the plasma membrane—HRAS—bile duct cancer	0.00106	0.00137	CbGpPWpGaD
Lithium—GSK3B—BDNF signaling pathway—HRAS—bile duct cancer	0.00104	0.00135	CbGpPWpGaD
Lithium—GSK3B—Focal Adhesion—EGFR—bile duct cancer	0.00104	0.00134	CbGpPWpGaD
Lithium—GSK3B—Fc epsilon receptor (FCERI) signaling—KRAS—bile duct cancer	0.00104	0.00134	CbGpPWpGaD
Lithium—GSK3B—DAP12 interactions—KRAS—bile duct cancer	0.00104	0.00134	CbGpPWpGaD
Lithium—GSK3B—Signaling by FGFR in disease—KRAS—bile duct cancer	0.00104	0.00134	CbGpPWpGaD
Lithium—GSK3B—Signaling by EGFR—KRAS—bile duct cancer	0.00103	0.00133	CbGpPWpGaD
Lithium—GSK3B—Signaling by EGFR in Cancer—KRAS—bile duct cancer	0.00102	0.00132	CbGpPWpGaD
Lithium—GSK3B—B Cell Activation—EGFR—bile duct cancer	0.00102	0.00132	CbGpPWpGaD
Lithium—GSK3B—Signaling by PDGF—KRAS—bile duct cancer	0.00101	0.00131	CbGpPWpGaD
Lithium—GSK3A—Signaling by NGF—EGFR—bile duct cancer	0.00101	0.00131	CbGpPWpGaD
Lithium—GSK3B—Signaling by SCF-KIT—IL6—bile duct cancer	0.00101	0.00131	CbGpPWpGaD
Lithium—GSK3B—Downstream signaling of activated FGFR—HRAS—bile duct cancer	0.00101	0.00131	CbGpPWpGaD
Lithium—GSK3A—NGF signalling via TRKA from the plasma membrane—IL6—bile duct cancer	0.00101	0.00131	CbGpPWpGaD
Lithium—GSK3B—Signaling by ERBB4—HRAS—bile duct cancer	0.000995	0.00129	CbGpPWpGaD
Lithium—GSK3B—Axon guidance—ERBB2—bile duct cancer	0.000976	0.00127	CbGpPWpGaD
Lithium—IMPA1—Metabolism—PTGS2—bile duct cancer	0.000973	0.00126	CbGpPWpGaD
Lithium—GSK3B—NGF signalling via TRKA from the plasma membrane—EGFR—bile duct cancer	0.000971	0.00126	CbGpPWpGaD
Lithium—GSK3B—Downstream signaling of activated FGFR—IL6—bile duct cancer	0.000967	0.00126	CbGpPWpGaD
Lithium—GSK3B—B Cell Activation—KRAS—bile duct cancer	0.000959	0.00124	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—RNF43—bile duct cancer	0.000956	0.00124	CbGpPWpGaD
Lithium—GSK3A—Signaling by NGF—KRAS—bile duct cancer	0.000955	0.00124	CbGpPWpGaD
Lithium—GSK3B—Insulin Signaling—HRAS—bile duct cancer	0.000955	0.00124	CbGpPWpGaD
Lithium—GSK3B—Developmental Biology—MET—bile duct cancer	0.000952	0.00124	CbGpPWpGaD
Lithium—GSK3B—Signaling by ERBB4—IL6—bile duct cancer	0.000952	0.00124	CbGpPWpGaD
Lithium—GSK3B—Downstream signal transduction—HRAS—bile duct cancer	0.00095	0.00123	CbGpPWpGaD
Lithium—GSK3B—Signaling by FGFR—HRAS—bile duct cancer	0.000945	0.00123	CbGpPWpGaD
Lithium—GSK3B—Signaling by ERBB2—HRAS—bile duct cancer	0.000941	0.00122	CbGpPWpGaD
Lithium—GSK3B—DAP12 signaling—HRAS—bile duct cancer	0.000936	0.00121	CbGpPWpGaD
Lithium—GSK3B—Downstream signaling events of B Cell Receptor (BCR)—HRAS—bile duct cancer	0.000923	0.0012	CbGpPWpGaD
Lithium—GSK3B—NGF signalling via TRKA from the plasma membrane—KRAS—bile duct cancer	0.000918	0.00119	CbGpPWpGaD
Lithium—GSK3B—Downstream signal transduction—IL6—bile duct cancer	0.000909	0.00118	CbGpPWpGaD
Lithium—GSK3B—Signaling by FGFR—IL6—bile duct cancer	0.000905	0.00117	CbGpPWpGaD
Lithium—GSK3B—Signaling by ERBB2—IL6—bile duct cancer	0.0009	0.00117	CbGpPWpGaD
Lithium—GSK3B—DAP12 signaling—IL6—bile duct cancer	0.000896	0.00116	CbGpPWpGaD
Lithium—GSK3B—Signaling by FGFR in disease—HRAS—bile duct cancer	0.000881	0.00114	CbGpPWpGaD
Lithium—GSK3B—DAP12 interactions—HRAS—bile duct cancer	0.000881	0.00114	CbGpPWpGaD
Lithium—GSK3B—Fc epsilon receptor (FCERI) signaling—HRAS—bile duct cancer	0.000881	0.00114	CbGpPWpGaD
Lithium—GSK3B—Signaling by EGFR—HRAS—bile duct cancer	0.000873	0.00113	CbGpPWpGaD
Lithium—GSK3B—Signaling by EGFR in Cancer—HRAS—bile duct cancer	0.000865	0.00112	CbGpPWpGaD
Lithium—GSK3B—Signaling by PDGF—HRAS—bile duct cancer	0.000861	0.00112	CbGpPWpGaD
Lithium—GSK3A—Disease—TGFBR2—bile duct cancer	0.000845	0.0011	CbGpPWpGaD
Lithium—GSK3B—DAP12 interactions—IL6—bile duct cancer	0.000843	0.00109	CbGpPWpGaD
Lithium—GSK3B—Fc epsilon receptor (FCERI) signaling—IL6—bile duct cancer	0.000843	0.00109	CbGpPWpGaD
Lithium—GSK3B—Signaling by FGFR in disease—IL6—bile duct cancer	0.000843	0.00109	CbGpPWpGaD
Lithium—GSK3A—Immune System—HGF—bile duct cancer	0.000841	0.00109	CbGpPWpGaD
Lithium—GSK3B—Axon guidance—MMP9—bile duct cancer	0.000837	0.00109	CbGpPWpGaD
Lithium—GSK3B—Signaling by EGFR—IL6—bile duct cancer	0.000835	0.00108	CbGpPWpGaD
Lithium—GSK3B—Focal Adhesion—HRAS—bile duct cancer	0.000832	0.00108	CbGpPWpGaD
Lithium—GSK3A—Innate Immune System—ERBB2—bile duct cancer	0.000832	0.00108	CbGpPWpGaD
Lithium—GSK3B—Circadian rythm related genes—TP53—bile duct cancer	0.000832	0.00108	CbGpPWpGaD
Lithium—GSK3A—Metabolism of proteins—MMP2—bile duct cancer	0.00083	0.00108	CbGpPWpGaD
Lithium—GSK3B—Signaling by EGFR in Cancer—IL6—bile duct cancer	0.000828	0.00107	CbGpPWpGaD
Lithium—GSK3B—Signaling by PDGF—IL6—bile duct cancer	0.000824	0.00107	CbGpPWpGaD
Lithium—GSK3B—Signaling by NGF—NRAS—bile duct cancer	0.00082	0.00106	CbGpPWpGaD
Lithium—GSK3B—B Cell Activation—HRAS—bile duct cancer	0.000815	0.00106	CbGpPWpGaD
Lithium—GSK3A—Signaling by NGF—HRAS—bile duct cancer	0.000812	0.00105	CbGpPWpGaD
Lithium—GSK3A—Disease—SMAD4—bile duct cancer	0.000799	0.00104	CbGpPWpGaD
Lithium—GSK3A—Adaptive Immune System—ERBB2—bile duct cancer	0.000799	0.00104	CbGpPWpGaD
Lithium—GSK3B—Developmental Biology—MMP2—bile duct cancer	0.000795	0.00103	CbGpPWpGaD
Lithium—GSK3B—NGF signalling via TRKA from the plasma membrane—HRAS—bile duct cancer	0.00078	0.00101	CbGpPWpGaD
Lithium—GSK3A—Signaling by NGF—IL6—bile duct cancer	0.000777	0.00101	CbGpPWpGaD
Lithium—GSK3B—Circadian rythm related genes—IL6—bile duct cancer	0.000761	0.000988	CbGpPWpGaD
Lithium—GSK3B—Signaling by NGF—EGFR—bile duct cancer	0.000747	0.000969	CbGpPWpGaD
Lithium—GSK3B—NGF signalling via TRKA from the plasma membrane—IL6—bile duct cancer	0.000747	0.000969	CbGpPWpGaD
Lithium—GSK3B—Axon guidance—NRAS—bile duct cancer	0.000742	0.000963	CbGpPWpGaD
Lithium—GSK3B—Signaling by NGF—KRAS—bile duct cancer	0.000706	0.000916	CbGpPWpGaD
Lithium—GSK3B—Developmental Biology—ERBB2—bile duct cancer	0.000696	0.000903	CbGpPWpGaD
Lithium—GSK3B—Axon guidance—EGFR—bile duct cancer	0.000676	0.000877	CbGpPWpGaD
Lithium—GSK3B—Cellular responses to stress—TP53—bile duct cancer	0.000669	0.000868	CbGpPWpGaD
Lithium—GSK3B—Axon guidance—KRAS—bile duct cancer	0.000639	0.000829	CbGpPWpGaD
Lithium—GSK3A—Innate Immune System—NRAS—bile duct cancer	0.000633	0.000821	CbGpPWpGaD
Lithium—GSK3B—Disease—TGFBR2—bile duct cancer	0.000624	0.00081	CbGpPWpGaD
Lithium—GSK3B—Immune System—HGF—bile duct cancer	0.000621	0.000806	CbGpPWpGaD
Lithium—GSK3B—Innate Immune System—ERBB2—bile duct cancer	0.000615	0.000798	CbGpPWpGaD
Lithium—GSK3B—Cellular responses to stress—IL6—bile duct cancer	0.000612	0.000794	CbGpPWpGaD
Lithium—GSK3A—Adaptive Immune System—NRAS—bile duct cancer	0.000608	0.000789	CbGpPWpGaD
Lithium—GSK3B—Signaling by NGF—HRAS—bile duct cancer	0.0006	0.000778	CbGpPWpGaD
Lithium—GSK3B—Developmental Biology—MMP9—bile duct cancer	0.000597	0.000775	CbGpPWpGaD
Lithium—GSK3A—Disease—NOS2—bile duct cancer	0.000595	0.000772	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—TGFBR2—bile duct cancer	0.000591	0.000767	CbGpPWpGaD
Lithium—GSK3B—Disease—SMAD4—bile duct cancer	0.000591	0.000766	CbGpPWpGaD
Lithium—GSK3B—Adaptive Immune System—ERBB2—bile duct cancer	0.00059	0.000766	CbGpPWpGaD
Lithium—GSK3A—Innate Immune System—EGFR—bile duct cancer	0.000577	0.000748	CbGpPWpGaD
Lithium—GSK3B—Signaling by NGF—IL6—bile duct cancer	0.000574	0.000745	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—GNAS—bile duct cancer	0.00057	0.00074	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—SMAD4—bile duct cancer	0.00056	0.000726	CbGpPWpGaD
Lithium—GSK3A—Adaptive Immune System—EGFR—bile duct cancer	0.000554	0.000718	CbGpPWpGaD
Lithium—GSK3A—Innate Immune System—KRAS—bile duct cancer	0.000545	0.000707	CbGpPWpGaD
Lithium—GSK3B—Axon guidance—HRAS—bile duct cancer	0.000543	0.000704	CbGpPWpGaD
Lithium—GSK3B—Developmental Biology—NRAS—bile duct cancer	0.00053	0.000687	CbGpPWpGaD
Lithium—GSK3A—Adaptive Immune System—KRAS—bile duct cancer	0.000523	0.000679	CbGpPWpGaD
Lithium—GSK3B—Axon guidance—IL6—bile duct cancer	0.00052	0.000674	CbGpPWpGaD
Lithium—GSK3B—Developmental Biology—TGFB1—bile duct cancer	0.000492	0.000638	CbGpPWpGaD
Lithium—GSK3A—Immune System—ERBB2—bile duct cancer	0.000485	0.000629	CbGpPWpGaD
Lithium—GSK3B—Developmental Biology—EGFR—bile duct cancer	0.000483	0.000626	CbGpPWpGaD
Lithium—GSK3B—Innate Immune System—NRAS—bile duct cancer	0.000468	0.000607	CbGpPWpGaD
Lithium—GSK3A—Innate Immune System—HRAS—bile duct cancer	0.000463	0.000601	CbGpPWpGaD
Lithium—GSK3B—Developmental Biology—KRAS—bile duct cancer	0.000456	0.000591	CbGpPWpGaD
Lithium—GSK3B—Adaptive Immune System—NRAS—bile duct cancer	0.000449	0.000583	CbGpPWpGaD
Lithium—GSK3A—Disease—ERBB2—bile duct cancer	0.000447	0.00058	CbGpPWpGaD
Lithium—GSK3A—Adaptive Immune System—HRAS—bile duct cancer	0.000445	0.000577	CbGpPWpGaD
Lithium—GSK3A—Innate Immune System—IL6—bile duct cancer	0.000443	0.000575	CbGpPWpGaD
Lithium—GSK3B—Disease—NOS2—bile duct cancer	0.00044	0.00057	CbGpPWpGaD
Lithium—GSK3A—Disease—PTGS2—bile duct cancer	0.000438	0.000568	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—TGFBR2—bile duct cancer	0.000437	0.000567	CbGpPWpGaD
Lithium—GSK3B—Innate Immune System—EGFR—bile duct cancer	0.000426	0.000553	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—GNAS—bile duct cancer	0.000422	0.000547	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—SMAD4—bile duct cancer	0.000414	0.000537	CbGpPWpGaD
Lithium—GSK3B—Adaptive Immune System—EGFR—bile duct cancer	0.000409	0.000531	CbGpPWpGaD
Lithium—GSK3B—Innate Immune System—KRAS—bile duct cancer	0.000403	0.000522	CbGpPWpGaD
Lithium—GSK3B—Developmental Biology—HRAS—bile duct cancer	0.000387	0.000503	CbGpPWpGaD
Lithium—GSK3B—Adaptive Immune System—KRAS—bile duct cancer	0.000387	0.000502	CbGpPWpGaD
Lithium—GSK3B—Developmental Biology—IL6—bile duct cancer	0.000371	0.000481	CbGpPWpGaD
Lithium—GSK3A—Immune System—NRAS—bile duct cancer	0.000369	0.000478	CbGpPWpGaD
Lithium—GSK3B—Immune System—ERBB2—bile duct cancer	0.000358	0.000465	CbGpPWpGaD
Lithium—GSK3B—Innate Immune System—HRAS—bile duct cancer	0.000342	0.000444	CbGpPWpGaD
Lithium—GSK3A—Disease—NRAS—bile duct cancer	0.00034	0.000442	CbGpPWpGaD
Lithium—GSK3A—Immune System—EGFR—bile duct cancer	0.000336	0.000436	CbGpPWpGaD
Lithium—GSK3B—Disease—ERBB2—bile duct cancer	0.000331	0.000429	CbGpPWpGaD
Lithium—GSK3B—Adaptive Immune System—HRAS—bile duct cancer	0.000329	0.000426	CbGpPWpGaD
Lithium—GSK3B—Innate Immune System—IL6—bile duct cancer	0.000328	0.000425	CbGpPWpGaD
Lithium—GSK3B—Disease—PTGS2—bile duct cancer	0.000323	0.000419	CbGpPWpGaD
Lithium—GSK3A—Immune System—KRAS—bile duct cancer	0.000317	0.000412	CbGpPWpGaD
Lithium—GSK3A—Disease—TGFB1—bile duct cancer	0.000316	0.00041	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—ERBB2—bile duct cancer	0.000313	0.000406	CbGpPWpGaD
Lithium—GSK3A—Disease—EGFR—bile duct cancer	0.00031	0.000402	CbGpPWpGaD
Lithium—GSK3A—Disease—KRAS—bile duct cancer	0.000293	0.00038	CbGpPWpGaD
Lithium—GSK3B—Immune System—NRAS—bile duct cancer	0.000272	0.000353	CbGpPWpGaD
Lithium—GSK3A—Immune System—HRAS—bile duct cancer	0.00027	0.00035	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—MMP9—bile duct cancer	0.000269	0.000349	CbGpPWpGaD
Lithium—GSK3A—Immune System—IL6—bile duct cancer	0.000258	0.000335	CbGpPWpGaD
Lithium—GSK3B—Disease—NRAS—bile duct cancer	0.000252	0.000326	CbGpPWpGaD
Lithium—GSK3A—Disease—HRAS—bile duct cancer	0.000249	0.000323	CbGpPWpGaD
Lithium—GSK3B—Immune System—EGFR—bile duct cancer	0.000248	0.000322	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—NRAS—bile duct cancer	0.000238	0.000309	CbGpPWpGaD
Lithium—GSK3A—Disease—IL6—bile duct cancer	0.000238	0.000309	CbGpPWpGaD
Lithium—GSK3B—Immune System—KRAS—bile duct cancer	0.000234	0.000304	CbGpPWpGaD
Lithium—GSK3B—Disease—TGFB1—bile duct cancer	0.000234	0.000303	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—ERBB2—bile duct cancer	0.000232	0.0003	CbGpPWpGaD
Lithium—GSK3B—Disease—EGFR—bile duct cancer	0.000229	0.000297	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—TGFB1—bile duct cancer	0.000222	0.000287	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—EGFR—bile duct cancer	0.000217	0.000282	CbGpPWpGaD
Lithium—GSK3B—Disease—KRAS—bile duct cancer	0.000216	0.000281	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—KRAS—bile duct cancer	0.000205	0.000266	CbGpPWpGaD
Lithium—GSK3B—Immune System—HRAS—bile duct cancer	0.000199	0.000259	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—MMP9—bile duct cancer	0.000199	0.000258	CbGpPWpGaD
Lithium—GSK3B—Immune System—IL6—bile duct cancer	0.000191	0.000247	CbGpPWpGaD
Lithium—GSK3B—Disease—HRAS—bile duct cancer	0.000184	0.000239	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—TP53—bile duct cancer	0.000182	0.000237	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—NRAS—bile duct cancer	0.000176	0.000229	CbGpPWpGaD
Lithium—GSK3B—Disease—IL6—bile duct cancer	0.000176	0.000228	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—HRAS—bile duct cancer	0.000174	0.000226	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—IL6—bile duct cancer	0.000167	0.000217	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—TGFB1—bile duct cancer	0.000164	0.000212	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—EGFR—bile duct cancer	0.00016	0.000208	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—KRAS—bile duct cancer	0.000152	0.000197	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—TP53—bile duct cancer	0.000135	0.000175	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—HRAS—bile duct cancer	0.000129	0.000167	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—IL6—bile duct cancer	0.000123	0.00016	CbGpPWpGaD
